Logo image of QTTB

Q32 BIO INC (QTTB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:QTTB - US7469641051 - Common Stock

3.2 USD
0 (0%)
Last: 12/26/2025, 7:11:13 PM
Fundamental Rating

1

QTTB gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. Both the profitability and financial health of QTTB have multiple concerns. QTTB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year QTTB has reported negative net income.
In the past year QTTB has reported a negative cash flow from operations.
QTTB had negative earnings in each of the past 5 years.
QTTB had a negative operating cash flow in each of the past 5 years.
QTTB Yearly Net Income VS EBIT VS OCF VS FCFQTTB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

QTTB has a worse Return On Assets (-75.58%) than 65.09% of its industry peers.
Industry RankSector Rank
ROA -75.58%
ROE N/A
ROIC N/A
ROA(3y)-62.55%
ROA(5y)-56.34%
ROE(3y)-332.65%
ROE(5y)-224.01%
ROIC(3y)N/A
ROIC(5y)N/A
QTTB Yearly ROA, ROE, ROICQTTB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for QTTB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QTTB Yearly Profit, Operating, Gross MarginsQTTB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

3

2. Health

2.1 Basic Checks

QTTB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, QTTB has more shares outstanding
The number of shares outstanding for QTTB has been reduced compared to 5 years ago.
Compared to 1 year ago, QTTB has a worse debt to assets ratio.
QTTB Yearly Shares OutstandingQTTB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
QTTB Yearly Total Debt VS Total AssetsQTTB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -5.88, we must say that QTTB is in the distress zone and has some risk of bankruptcy.
QTTB's Altman-Z score of -5.88 is on the low side compared to the rest of the industry. QTTB is outperformed by 64.53% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.88
ROIC/WACCN/A
WACC8.79%
QTTB Yearly LT Debt VS Equity VS FCFQTTB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 4.71 indicates that QTTB has no problem at all paying its short term obligations.
QTTB has a Current ratio of 4.71. This is comparable to the rest of the industry: QTTB outperforms 54.15% of its industry peers.
A Quick Ratio of 4.71 indicates that QTTB has no problem at all paying its short term obligations.
QTTB has a Quick ratio of 4.71. This is comparable to the rest of the industry: QTTB outperforms 55.66% of its industry peers.
Industry RankSector Rank
Current Ratio 4.71
Quick Ratio 4.71
QTTB Yearly Current Assets VS Current LiabilitesQTTB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

QTTB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 84.96%, which is quite impressive.
The Revenue for QTTB has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)84.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.9%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, QTTB will show a very strong growth in Earnings Per Share. The EPS will grow by 20.32% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y85.2%
EPS Next 2Y30.37%
EPS Next 3Y20.32%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
QTTB Yearly Revenue VS EstimatesQTTB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 10M 20M 30M
QTTB Yearly EPS VS EstimatesQTTB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

QTTB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year QTTB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QTTB Price Earnings VS Forward Price EarningsQTTB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QTTB Per share dataQTTB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3 -4 -5

4.3 Compensation for Growth

QTTB's earnings are expected to grow with 20.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.37%
EPS Next 3Y20.32%

More info and screens

0

5. Dividend

5.1 Amount

QTTB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Q32 BIO INC

NASDAQ:QTTB (12/26/2025, 7:11:13 PM)

3.2

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/bmo
Earnings (Next)05-06 2026-05-06
Inst Owners46.01%
Inst Owner Change-6.09%
Ins Owners0.58%
Ins Owner Change-4.45%
Market Cap39.36M
Revenue(TTM)N/A
Net Income(TTM)-59.76M
Analysts82.5
Price Target11.56 (261.25%)
Short Float %3.19%
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.47%
Min EPS beat(2)24.69%
Max EPS beat(2)28.26%
EPS beat(4)2
Avg EPS beat(4)4.36%
Min EPS beat(4)-33.54%
Max EPS beat(4)28.26%
EPS beat(8)3
Avg EPS beat(8)-70.48%
EPS beat(12)5
Avg EPS beat(12)-48.8%
EPS beat(16)9
Avg EPS beat(16)-32.31%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.33%
PT rev (3m)13.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)15.39%
EPS NY rev (3m)15.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.44
EYN/A
EPS(NY)-5.7
Fwd EYN/A
FCF(TTM)-5.31
FCFYN/A
OCF(TTM)-5.3
OCFYN/A
SpS0
BVpS-0.33
TBVpS-0.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -75.58%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.55%
ROA(5y)-56.34%
ROE(3y)-332.65%
ROE(5y)-224.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.71
Quick Ratio 4.71
Altman-Z -5.88
F-Score1
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)51.62%
Cap/Depr(5y)46.08%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.9%
EPS Next Y85.2%
EPS Next 2Y30.37%
EPS Next 3Y20.32%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-133.59%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.2%
OCF growth 3YN/A
OCF growth 5YN/A

Q32 BIO INC / QTTB FAQ

Can you provide the ChartMill fundamental rating for Q32 BIO INC?

ChartMill assigns a fundamental rating of 1 / 10 to QTTB.


What is the valuation status of Q32 BIO INC (QTTB) stock?

ChartMill assigns a valuation rating of 1 / 10 to Q32 BIO INC (QTTB). This can be considered as Overvalued.


How profitable is Q32 BIO INC (QTTB) stock?

Q32 BIO INC (QTTB) has a profitability rating of 0 / 10.


What is the expected EPS growth for Q32 BIO INC (QTTB) stock?

The Earnings per Share (EPS) of Q32 BIO INC (QTTB) is expected to grow by 85.2% in the next year.